Gilead (GILD) to Showcase New Cancer Therapy Data

On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company, unneurotic with its subsidiary Kite, volition contiguous implicit 25 abstracts astatine the 2026 ASCO Annual Meeting (May 29 – June 2) and the EHA Congress (June 11 – 14), showcasing advancement successful crab therapies. Key ASCO presentations see caller late-stage Phase 3 analyses for Trodelvy successful first-line metastatic triple-negative bosom cancer, focusing connected semipermanent progression-free survival. For the archetypal time, Kite volition besides present manufacturing consistency information for anito-cel, an investigational CAR T-cell therapy for aggregate myeloma. In addition, EHA updates volition showcase the results regarding the durability and information of an enhanced CAR T-cell therapy called KITE-753 that targets relapsed/refractory B-cell lymphoma.

In a caller development, Gilead Sciences, Inc. (NASDAQ:GILD) announced caller Phase 3 interim information showing Livdelzi achieved precocious and sustained normalization of a cardinal liver marker (ALP) successful superior biliary cholangitis patients. According to the results, the cause was well-tolerated implicit 2 years of treatment.

Founded successful 1987 and headquartered successful California, Gilead Sciences Inc. (NASDAQ:GILD) is simply a cause shaper that develops medicines for unmet aesculapian needs. The institution provides treatments for HIV-1, chronic hepatitis C, superior biliary cholangitis, chronic hepatitis B, and superior invasive fungal infections. It has paid uninterrupted quarterly dividends for 10 consecutive years.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Leopold Aschenbrenner’s Portfolio: 10 Best Stocks to Buy and Steve Cohen Stock Portfolio: Top 10 Stock Picks

Disclosure: None. Follow Insider Monkey connected Google News.